ATAI$3.71
Chart
Performance
Key Stats
AI ATAI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldAtai Life Sciences is in a high-growth thematic area (mental health treatments), but its current financial performance and valuation metrics suggest a 'Hold' rating. While recent performance shows significant gains, the company is still unprofitable with negative earnings per share, indicating substantial risk. The technicals show mixed signals, with short-term bearish indicators despite a longer-term positive trend. Investors should closely monitor clinical trial progress and future earnings reports.
Thematic
Atai Life Sciences is at the forefront of the rapidly growing mental health and psychedelic therapeutics market. This sector has strong secular tailwinds driven by increasing awareness of mental health issues and the potential of novel treatment modalities. The company's pipeline focuses on significant unmet needs, positioning it well for future growth if clinical trials are successful.
Fundamental
The company is currently unprofitable, with significant negative EPS and net income. While revenue has been minimal and inconsistent, it's important to note this is typical for early-stage biopharmaceutical companies. The balance sheet shows substantial cash reserves, which is a positive for funding ongoing research and development, but the debt levels are also increasing.
Technical
The stock is in a strong upward trend over the past year, as indicated by the significant performance gains (1M: 57.11%, 6M: 143.79%, 1Y: 122.33%). However, recent short-term technical indicators (1D, 5m, 15m) suggest a potential for a pullback, with several moving averages indicating 'Sell' and RSI in bearish territory for shorter timeframes. The stock is currently trading below key moving averages on very short-term charts.
| Factor | Score |
|---|---|
| Mental Health Therapeutics Market Growth | 90 |
| Pipeline Progression & Success | 70 |
| Regulatory Landscape | 65 |
| Competitive Positioning | 60 |
| Innovation & R&D Focus | 85 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Revenue Growth | 20 |
| Balance Sheet Health | 40 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 50 |
| Volume | 70 |
| Short-term Indicators | 30 |
| Performance | 80 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Short-Term Performance Momentum
The stock has shown robust short-term performance, with a 1-month return of 57.11% and a year-to-date return of 120.94%. This indicates significant recent investor interest and positive price action.
Negative P/E Ratio (Potential Growth Opportunity)
The trailing Price-to-Earnings (P/E) ratio is not applicable due to negative earnings (EPS TTM of -0.91). This is common for clinical-stage companies and suggests a focus on future growth potential rather than current profitability. A negative P/E can be seen as an opportunity if the company successfully commercializes its pipeline.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with a TTM net income of -$91.675 million and a reported EPS of -$0.15 for Q2 2025, which was better than the estimated -$0.18. However, the overall trend points to significant operational costs outpacing revenue.
High Price-to-Sales (P/S) Ratio
The trailing P/S ratio is 469.7, and the P/S for 2024 is 916.1. These extremely high ratios, due to minimal revenue, reflect a valuation heavily based on future potential rather than current sales, indicating a high degree of market expectation and risk.
Calendar
August 2025
13
Next Earnings Date
H: $-0.08
A: $-0.12
L: $-0.18
Profile
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Seasonals
Price Target
9.83 USD
The 39 analysts offering 1 year price forecasts for ATAI have a max estimate of 12.00 and a min estimate of 7.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor specializing in the development of psilocybin-based therapies for treatment-resistant depression (TRD), similar to ATAI's focus on psychedelic compounds for mental health.
Weight: 90
Key player in the psychedelic R&D space, developing novel psychedelic-derived therapies (e.g., LSD, MDMA derivatives) for various mental health conditions and addiction.
Weight: 85
Biopharmaceutical company focused on developing and commercializing novel medicines for brain health disorders, including postpartum depression and major depressive disorder (MDD), making them a close peer in the mental health therapeutics space.
Weight: 80
Developing novel, differentiated therapies for the management of central nervous system (CNS) disorders, including major depressive disorder (MDD) and narcolepsy, which are areas of interest for ATAI.